المؤلفون: V. A. Kuzmina, E. V. Reutova, K. K. Laktionov, M. A. Ardzinba, В. А. Кузьмина, Е. В. Реутова, К. К. Лактионов, М. С. Ардзинба

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 153-160 ; Медицинский Совет; № 10 (2024); 153-160 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: GEOMETRY mono-1, METex14 mutation, targeted therapy, capmatinib, мутация METex14, таргетная терапия, капматиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8407/7398; Fujino T, Suda K, Mitsudomi T. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs. 2020;25(3):229–249. https://doi.org/10.1080/14728214.2020.1791821.; Skead G, Govender D. Gene of the month: MET. J Clin Pathol. 2015;68(6):405–409. https://doi.org/10.1136/jclinpath-2015-203050.; Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45. https://doi.org/10.1186/s12943-018-0796-y.; Matsumoto K, Ziober BL, Yao CC, Kramer RH. Growth factor regulation of integrin-mediated cell motility. Cancer Metastasis Rev. 1995;14(3):205–217. https://doi.org/10.1007/BF00690292.; Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. 2014;7:1001–1014. https://doi.org/10.2147/OTT.S44941.; Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res. 2016;22(12):3048–3056. https://doi.org/10.1158/1078-0432.CCR-15-2061.; Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21–35. https://doi.org/10.1177/1758834011422557.; Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017;16(4):555–565. https://doi.org/10.1158/1535-7163.MCT-16-0472.; Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol. 2017;12(1):15–26. https://doi.org/10.1016/j.jtho.2016.10.014.; Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM et al. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020;26(11):2535–2545. https://doi.org/10.1158/1078-0432.CCR-19-3906.; Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J et al. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol. 2016;34(8):794–802. https://doi.org/10.1200/JCO.2015.62.0674.; Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer. 2018;123:76–82. https://doi.org/10.1016/j.lungcan.2018.07.006.; Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021;5:653–663. https://doi.org/10.1200/PO.20.00516.; Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102. https://doi.org/10.1016/j.lungcan.2019.05.011.; Porter J. Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opin Ther Pat. 2010;20(2):159–177. https://doi.org/10.1517/13543770903514137.; Bahcall M, Paweletz CP, Kuang Y, Taus LJ, Sim T, Kim ND et al. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022;21(2):322–335. https://doi.org/10.1158/1535-7163.MCT-21-0344.; Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51. https://doi.org/10.1038/s41591-019-0716-8.; Landi L, Chiari R, Tiseo M, D’Incà F, Dazzi C, Chella A et al. Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clin Cancer Res. 2019;25(24):7312–7319. https://doi.org/10.1158/1078-0432.CCR-19-0994.; Vuong HG, Nguyen TQ, Nguyen HC, Nguyen PT, Ho ATN, Hassell L. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Target Oncol. 2020;15(5):589–598. https://doi.org/10.1007/s11523-020-00745-7.; Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127–7138. https://doi.org/10.1158/1078-0432.CCR-11-1157.; Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(10):944–957. https://doi.org/10.1056/NEJMoa2002787.; McKenzie A, Fisher A, Correll M, Jones C, Correia J, Thurber J, Misch A et al. Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy. J Clin Oncol. 2020;38(15):9613. https://doi.org/10.1200/JCO.2020.38.15_suppl.9613.; Sabari JK, Montecalvo J, Chen R, Dienstag JA, Mrad C, Bergagnini I et al. PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC). J Clin Oncol. 2017;35:8512–8512. https://doi.org/10.1200/JCO.2017.35.15_suppl.8512.; Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–2091. https://doi.org/10.1093/annonc/mdy334.; Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137–147. https://doi.org/10.1056/NEJMoa2304594.; Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41(10):1830–1840. https://doi.org/10.1200/JCO.22.02186.; Solomon BJ, Ahn JS, Dziadziuszko R, Barlesi F, Nishio M, Lee DH et al. LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(2):S1295–S1296 https://doi.org/10.1016/j.annonc.2023.10.051.; Lee JM, Awad MM, Saliba TR, Caro N, Banerjee H, Kelly K. Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial. J Clin Oncol. 2022;40(16 Suppl.):TPS8590. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS8590.; Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M et al. Real-world experience with capmatinib in MET exon 14-mutated nonsmall cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;14:17588359221103206. https://doi.org/10.1177/17588359221103206.; https://www.med-sovet.pro/jour/article/view/8407

الاتاحة: https://www.med-sovet.pro/jour/article/view/8407
https://doi.org/10.21518/ms2024-244

المؤلفون: K. K. Laktionov, E. V. Reutova, К. К. Лактионов, Е. В. Реутова

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 34-40 ; Медицинский Совет; № 11 (2023); 34-40 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: интракраниальная активность, METex14 mutation, MET amplification, capmatinib, intracranial activity, мутация МЕТex14, амплификация МЕТ, капматиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7666/6800; Finocchiaro G., Toschi L., Gianoncelli L., Baretti M., Santoro А. Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med. 2015;3(6):83. https://doi.org/10.3978/j.issn.2305-5839.2015.03.43.; Drilon A., Cappuzzo F., Ou S.I., Camidge D.R. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2017;12(1):15–26. https://doi.org/10.1016/j.jtho.2016.10.014.; Liu X., Jia Y., Stoopler M.B., Shen Y., Cheng H., Chen J. et al. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802. https://doi.org/10.1200/JCO.2015.62.0674.; Byers L.A., Diao L., Wang J., Saintigny P., Girard L., Peyton M. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifi es Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–290. https://doi.org/10.1158/1078-0432.; Tong J.H., Yeung S.F., Chan A.W., Chung L.Y., Chau S.L., Ming Lung R.W. et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048–3056. https://doi.org/10.1158/1078-0432.CCR-15-2061.; Wolf J., Baik C., Heist R.S., Neal J.W., Mansfield A.S., Buettner R. et al. Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). Presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics, Dublin, November 13–16, 2018. Available at: https://stanfordhealthcare.org/publications/507/507112.html.; Sabari J.K., Leonardi G.C., Shu C.A., Umeton R., Montecalvo J., Ni A. et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085–2091. https://doi.org/10.1093/annonc/mdy334.; Reis H., Metzenmacher M., Goetz M., Savvidou N., Darwiche K., Aigner C. et al. MET expression in advanced nonsmall-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin Lung Cancer. 2018;19(4):e441–e4633. https://doi.org/10.1016/j.cllc.2018.03.010.; Шнейдер О.В., Камилова Т.А., Голота А.С., Сарана А.М., Щербак С.Г. Биомаркеры и таргетная терапия при раке легких. Физическая и реабилитационная медицина, медицинская реабилитация. 2021;3(1):74–94. https://doi.org/10.36425/rehab63268.; Wang S.X.Y., Zhang B.M., Wakelee H.A., Koontz M.Z., Pan M., Diehn M. et al. Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small-Cell Lung Cancers with Response to Crizotinib and Cabozantinib. Anticancer Drugs. 2019;30(5):537–541. https://doi.org/10.1097/CAD.0000000000000765.; Waqar S.N., Morgensztern D., Sehn J. MET Mutation Associated with Responsiveness to Crizotinib. J Thorac Oncol. 2015;10(5):e29–e31. https://doi.org/10.1097/JTO.0000000000000478.; Drilon A., Clark J.W., Weiss J., Ou S.-H.I., Camidge D.R., Solomon B.J. et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51. https://doi.org/10.1038/s41591-019-0716-8.; Liu X., Wang Q., Yang G., Marando С., Koblish H.K., Hall L.M. et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127–7138. https://doi.org/10.1158/1078-0432.CCR-11-1157.; Baltschukat S., Engstler B.S., Huang A., Hao H.-X., Tam A., Wang H.Q. et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25(10):3164–3175. https://doi.org/10.1158/1078-0432.CCR-18-2814.; Wolf J., Seto T., Han J.-Y., Reguart N., Garon E., Groen H.J.M. et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. J Engl J Med. 2020;383(10):944–957. https://doi.org/10.1056/nejmoa2002787.; Heist R.S., Seto T., Han J.-Y., Reguart N., Garon E.B., Groen H.J.M. et al. CMET-22. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study. Neuro Oncol. 2019;21(6 Suppl.):vi56. https://doi.org/10.1093%2Fneuonc%2Fnoz175.223.; Shih K., Falchook G.S., Becker K., Battiste J., Pearlman M., Shastry M., Burris H. A phase Ib study evaluating the c-MET inhibitor INC280 in combination with bevacizumab in glioblastoma multiforme (GBM) patients. Neuro Oncol. 2016;18(6):vi11–vi12. https://doi.org/10.1093/neuonc/now212.043.; Schuler M., Berardi R., Lim W.-T., de Jonge M., Bauer T.M., Azaro A. et al. Molecular correlates of response to capmatinib in advanced non-smallcell lung cancer: clinical and biomarker results from a phase I trial. Ann Oncol. 2020;31(6):789–797. https://doi.org/10.1016/j.annonc.2020.03.293.; Орлов С.В., Mусаелян А., Кочесокова Д.Л., Одинцова С.В., Загребин Ф.A., Тюрин В.И. и др. Капматиниб у пациентов с MET-положительным распространенным немелкоклеточныи раком легкого: анализ российской группы в исследовании GEOMETRY MONO-1. Вопросы онкологии. 2022;68(6):758–768. https://doi.org/10.37469/0507-3758-2022-68-6-758-767.; Paik P.K., Goyal R.K., Cai B., Price M.A., Davis K.L., Ansquer V.D. et al. Realworld outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023;19(3):217–228. https://doi.org/10.2217/fon-2022-1133.; Awad M.M., Leonardi G.C., Kravets S., Dahlberg S.E., Drilon A., Noonan S.A. et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102. https://doi.org/10.1016/j.lungcan.2019.05.011.; Dagogo-Jack I., Moonsamy P., Gainor J.F., Lennerz J.K., Piotrowska Z., Lin J.J. et al. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021;16(5):850–859. https://doi.org/10.1016/j.jtho.2021.01.1605.; Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Демидова И.А., Деньгина Н.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2022;12(3s2-1):41–59. https://doi.org/10.18027/2224-5057-2022-12-3s2-41-59.; Kalemkerian G.P., Narula N., Kennedy E.B., Biermann W.A., Donington J., Leighl N.B. et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911–919. https://doi.org/10.1200/JCO.2017.76.7293.; Wu Y.L., Planchard D., Lu S., Sun H., Yamamoto N., Kim D.W. et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(2):171–210. https://doi.org/10.1093/annonc/mdy554.; Gutierrez M.E., Choi K., Lanman R.B., Licitra E.J., Skrzypczak S.M., Pe Benito R. et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651–659. https://doi.org/10.1016/j.cllc.2017.04.004.; Miller T.E., Yang M., Bajor D., Friedman J.D., Chang R.Y.C., Dowlati A. et al. Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. J Clin Pathol. 2018;71(12):1108–1115. https://doi.org/10.1136/jclinpath-2018-205396.; Ferry-Galow K.V., Datta V., Makhlouf H.R., Wright J., Wood B.J., Levy E. et al. What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials? J Oncol Pract. 2018;14(11):JOP1800092. https://doi.org/10.1200/JOP.18.00092.; Noonan S.A., Berry L., Lu X., Gao D., Barón A.E., Chesnut P. et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J Thorac Oncol. 2016;11(8):1293–1304. https://doi.org/10.1016/j.jtho.2016.04.033.; Wu Y.-L., Zhang L., Kim D.-W., Liu X., Lee D.H., Yang J.C.-H. et al. Phase Ib/ II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFRmutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36(31):3101–3109. https://doi.org/10.1200/JCO.2018.77.7326.; https://www.med-sovet.pro/jour/article/view/7666

الاتاحة: https://www.med-sovet.pro/jour/article/view/7666
https://doi.org/10.21518/ms2023-194